Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.